Epidemiology of Huntington's disease in the US Medicaid population

loci

Alex Exuzides,¹ Sheila Reiss Reddy,² Eunice Chang,² Caleb Paydar,² George Yohrling³

(1) Genentech Inc, South San Francisco, CA, USA;


(2) Partnership for Health Analytic Research (PHAR), LLC, Beverly Hills, CA, USA;

(3) Huntington's Disease Society of America (HDSA), New York, NY, USA.




Genentech

A Member of the Roche C




· Given this dearth of evidence, research is needed to generate current estimates of HD prevalence in US populations.

Prevalence of HD in US Medicaid population in 2014 is estimated to be 15.2 per 100,000 people (Figure 1).




Individuals with late-stage disease had the highest prevalence in both male and female cohorts (Figure 2).



HD prevalence increased by age category (Figure 3).

55-64 years of age) and disease stage (early, middle, late).6



* All three disease stages were combined to adhere to Centers for Medicare & Medicaid Services (CMS) cell size suppression policy. † Early and middle disease stages were combined to adhere to CMS cell size suppression policy. Prevalence estimates reported b stage may add up to more than the total due to rounding error

Figure 2. Prevalence of HD among Medicaid beneficiaries in 2014, by sex

Figure 3. Prevalence of HD among Medicaid beneficiaries in 2014, by age

Acknowledgments

We thank all the patients who participate in our studies and their families. This study is funded by F. Hoffmann-La Roche Ltd. The authors thank Greg Rowe, of MediTech Media, UK for providing editorial support for this poster, which was funded by F. Hoffmann-La Roche Ltd in accordance with Good Publication Practice (GPP3) quidelines (http://www.ismpp.org/qpp3).

Abbreviations

(Q

RESULT

CMS, Centers for Medicare & Medicaid Services; HD, Huntington's disease; ICD-9/10-CM: 333.4, International Classification of Diseases, Ninth Revision, Clinical Modification code: 333.4.

References

- Bates GP, et al. Nat Rev Dis Primers. 2015; 1:15005 Roos RA. Orphanet J Rare Dis. 2010; 5:40;
- Keum JW. et al. Hum Genet. 2016: 98:287-298
- Bruzelius MPH. Mov Disord. 2019; 34:858-865 Fisher ER. Mov Disord. 2014; 29: 105-114;
 - Divino V, et al. J Med Econ. 2013; 16:1043-1050



Please scan using your QR reader application to access this poster on your mobile device. NB: there may be associated costs for downloading data. These costs may be high if you are using your smartphone abroad

Please check your mobile data tariff or contact your service provider for more details. Alternatively this can be accessed at https://bit.lv/2OgtzdT.